Zhen Gong

This inventor holds 13 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 9 EPO patents. Top assignees: Glaxosmithkline Intellectual Property Development Limited, Medshine Discovery Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Active years: 2015-2025.

USPTO Granted Patents = 13 (Patent Applications = 5)

% Patents Active = 76.9

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 9 (Patent Applications = 14)

Average Co-Inventor Count = 7.6

ph-index = 2

Forward Citations = 53(Granted Patents)

Location History:

Jiangsu, CN (2021)
Shanghai, CN (2015 - 2024)

Company Filing History:

3 out of 240

Glaxosmithkline Intellectual Property Development Limited

patents

2 out of 71

Medshine Discovery Inc.

patents

1 out of 121

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

patents

4. 1 out of 1

Chia Tai Tianqing Pharmaceutical Group Go., Ltd.

patent

5. 1 out of 32

Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.

patents

6. 1 out of 2

Cstone Pharmaceutical (Suzhou) Co., Ltd.

patents

7. 1 out of 9

Cstone Pharmaceuticals

patents

8. 1 out of 7

Cstone Pharmaceuticals (Shanghai) Co., Ltd.

patents

9. 1 out of 13

Guangdong Raynovent Biotech Co., Ltd.

patents

10. 1 out of 24

Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

patents

11. 1 out of 14

Shanghai Hansoh Biomedical Co., Ltd.

patents

12. 1 out of 2

Wuxi Life Fountain Biotech Co., Ltd

patents

13. 1 out of 15

Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 2015-2025

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12497366 - Nitrogen-containing heterocyclic derivative inhibitor, preparation method therefor and use thereof (2025-12-16),

2. 12312347 - Azaindole derivative and use thereof as FGFR and C-Met inhibitor (2025-05-27),

3. 11932652 - Pyrrolidinyl urea derivatives and application thereof in TrkA-related diseases (2024-03-19),

4. 11891398 - 2,3-dihydro-1H-pyrrolizine-7-formamide derivative and application thereof (2024-02-06),

5. 11680070 - Thieno[2,3-c]pyridazin-4(1H)-one derivative and application thereof (2023-06-20),

6. 11312726 - Thienodiazepine derivatives and application thereof (2022-04-26),

7. 11230544 - Substituted 1,3,4-thiadiazoles as GLS1 inhibitors (2022-01-25),

8. 11021486 - Coumarin-like cyclic compound as MEK inhibitor and use thereof (2021-06-01),

9. 11014943 - Azetidine derivative (2021-05-25),

10. 10526320 - Pyrrolidine derivatives as PPAR agonists (2020-01-07),

11. 10294236 - Compounds as rearranged during transfection (RET) inhibitors (2019-05-21),

12. 9879021 - Compounds as rearranged during transfection (RET) inhibitors (2018-01-30),

13. 8937071 - Compounds as rearranged during transfection (RET) inhibitors (2015-01-20),

Title: Zhen Gong: Innovator in Pharmaceutical Development

Introduction

Zhen Gong is a prominent inventor based in Shanghai, CN, known for his significant contributions to the field of pharmaceutical development. With a total of 13 patents to his name, he has made remarkable strides in creating innovative solutions for various medical challenges.

Latest Patents

Among his latest patents is a nitrogen-containing heterocyclic derivative inhibitor, which includes a preparation method and its use in treating cardiovascular and cerebrovascular diseases. This invention details a compound represented by a specific general formula, along with its pharmaceutical composition and application as an inhibitor. Another notable patent is for an azaindole derivative, which serves as an FGFR and C-Met inhibitor. This series of pyrazolopymidine derivatives is designed for use in medicaments aimed at treating diseases associated with FGFR and C-Met.

Career Highlights

Zhen Gong has worked with reputable companies such as GlaxoSmithKline Intellectual Property Development Limited and Medshine Discovery Inc. His experience in these organizations has allowed him to refine his expertise in pharmaceutical innovation and patent development.

Collaborations

Throughout his career, Zhen has collaborated with notable professionals, including Jian Li and Shuhui Chen. These partnerships have contributed to his success and the advancement of his inventions.

Conclusion

Zhen Gong's work exemplifies the spirit of innovation in the pharmaceutical industry. His patents and collaborations reflect his commitment to improving healthcare through scientific advancements.